JP2018535684A - ＣＤ３４陽性成体幹細胞の増殖を誘導する薬物としてのｍｉｃｒｏＲＮＡ前駆体の使用 - Google Patents

ＣＤ３４陽性成体幹細胞の増殖を誘導する薬物としてのｍｉｃｒｏＲＮＡ前駆体の使用 Download PDF

Info

Publication number
JP2018535684A
JP2018535684A JP2018528746A JP2018528746A JP2018535684A JP 2018535684 A JP2018535684 A JP 2018535684A JP 2018528746 A JP2018528746 A JP 2018528746A JP 2018528746 A JP2018528746 A JP 2018528746A JP 2018535684 A JP2018535684 A JP 2018535684A
Authority
JP
Japan
Prior art keywords
mir
cells
rna
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018528746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535684A5 (enExample
Inventor
リン、シー−ラン
チャン、ドナルド
ティーエス ウー、デイビッド
ティーエス ウー、デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/048,964 external-priority patent/US10519440B2/en
Priority claimed from US15/167,226 external-priority patent/US9879263B2/en
Application filed by Individual filed Critical Individual
Publication of JP2018535684A publication Critical patent/JP2018535684A/ja
Publication of JP2018535684A5 publication Critical patent/JP2018535684A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018528746A 2015-12-02 2016-08-31 ＣＤ３４陽性成体幹細胞の増殖を誘導する薬物としてのｍｉｃｒｏＲＮＡ前駆体の使用 Pending JP2018535684A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562262280P 2015-12-02 2015-12-02
US62/262,280 2015-12-02
US15/048,964 2016-02-19
US15/048,964 US10519440B2 (en) 2012-08-10 2016-02-19 Composition and method of using miR-302 precursors as drugs for treating Alzheimer's diseases
US15/167,226 US9879263B2 (en) 2011-08-12 2016-05-27 Use of microRNA precursors as drugs for inducing CD34-positive adult stem cell expansion
US15/167,226 2016-05-27
PCT/US2016/049583 WO2017095489A1 (en) 2015-12-02 2016-08-31 Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansion

Publications (2)

Publication Number Publication Date
JP2018535684A true JP2018535684A (ja) 2018-12-06
JP2018535684A5 JP2018535684A5 (enExample) 2019-10-10

Family

ID=56896813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018528746A Pending JP2018535684A (ja) 2015-12-02 2016-08-31 ＣＤ３４陽性成体幹細胞の増殖を誘導する薬物としてのｍｉｃｒｏＲＮＡ前駆体の使用

Country Status (5)

Country Link
EP (1) EP3384026A1 (enExample)
JP (1) JP2018535684A (enExample)
CN (1) CN108431227A (enExample)
TW (1) TWI720075B (enExample)
WO (1) WO2017095489A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022189717A (ja) * 2021-06-12 2022-12-22 リン シー‐ラン ｉＰＳ細胞の生成に使用される新規ＲＮＡ組成物およびその製造方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11624067B2 (en) 2008-05-07 2023-04-11 Shi-Lung Lin In-vitro induction of adult stem cell expansion and derivation
JP7718819B2 (ja) * 2018-07-02 2025-08-05 リン、シー－ラン 成体幹細胞の拡大と誘導のインビトロでの誘発
CN112430596B (zh) * 2019-08-26 2025-10-28 中国科学院上海营养与健康研究所 一类小rna分子及其类似物在抗衰老中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014106011A1 (en) * 2012-12-28 2014-07-03 Shi-Lung Lin Production and extraction of microrna precursor as drug for cancer therapy
JP2014530596A (ja) * 2011-08-12 2014-11-20 メロ バイオテクノロジー インコーポレイテッドＭｅｌｌｏ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ，Ｉｎｃ． 原核細胞内の真核ｐｏｌ−２プロモーターからの誘導可能な発現
US20150132805A1 (en) * 2012-08-10 2015-05-14 Mello Biotech Taiwan Co., Ltd. Composition for producing microrna precursors as drugs for enhancing wound healing and production method of the microrna precursors
JP2015530988A (ja) * 2012-08-10 2015-10-29 リン、シー−ランLIN, Shi−Lung 新規な治療用抗癌薬の製造及び使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE484572T1 (de) 1997-04-16 2010-10-15 Unigene Lab Inc Direkte expression von peptiden ins kulturmedium
US9453219B2 (en) 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
CN101970664B (zh) * 2008-01-16 2013-08-21 林希龙 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞
US9879263B2 (en) * 2011-08-12 2018-01-30 Mello Biotechnology, Inc. Use of microRNA precursors as drugs for inducing CD34-positive adult stem cell expansion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530596A (ja) * 2011-08-12 2014-11-20 メロ バイオテクノロジー インコーポレイテッドＭｅｌｌｏ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ，Ｉｎｃ． 原核細胞内の真核ｐｏｌ−２プロモーターからの誘導可能な発現
US20150132805A1 (en) * 2012-08-10 2015-05-14 Mello Biotech Taiwan Co., Ltd. Composition for producing microrna precursors as drugs for enhancing wound healing and production method of the microrna precursors
JP2015530988A (ja) * 2012-08-10 2015-10-29 リン、シー−ランLIN, Shi−Lung 新規な治療用抗癌薬の製造及び使用
WO2014106011A1 (en) * 2012-12-28 2014-07-03 Shi-Lung Lin Production and extraction of microrna precursor as drug for cancer therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. Vol.10, No.6, e0127986, JPN6020037886, June 2015 (2015-06-01), pages 1 - 15, ISSN: 0004689162 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 19, JPN6020037884, 2011, pages 17359 - 17364, ISSN: 0004361600 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022189717A (ja) * 2021-06-12 2022-12-22 リン シー‐ラン ｉＰＳ細胞の生成に使用される新規ＲＮＡ組成物およびその製造方法
JP7364198B2 (ja) 2021-06-12 2023-10-18 リン シー‐ラン ｉＰＳ細胞の生成に使用される新規ＲＮＡ組成物およびその製造方法

Also Published As

Publication number Publication date
TWI720075B (zh) 2021-03-01
CN108431227A (zh) 2018-08-21
TW201735932A (zh) 2017-10-16
WO2017095489A1 (en) 2017-06-08
EP3384026A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
CA2769289C (en) Development of universal cancer drugs and vaccines
JP6185468B2 (ja) 原核細胞内においてヘアピン様ｒｎａを発現させる方法及び組成物
US9422559B2 (en) Production and utilization of a novel anti-cancer drug in therapy
TWI689308B (zh) 包含ｍｉｒ-３０２前驅體的組合物在製造用於肺癌治療之藥物上的用途
TWI720075B (zh) 使用微核醣核酸前驅物作爲誘導ｃｄ３４陽性成體幹細胞增殖之藥物
US9399773B2 (en) Production and extraction of MicroRNA precursor as drug for cancer therapy
JP2020037599A (ja) 新規な治療用抗癌薬の製造及び使用
US20200165607A1 (en) Composition and method of using mir-302 precursors as anti-cancer drugs for treating human lung cancer
US10196662B2 (en) Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
US9879263B2 (en) Use of microRNA precursors as drugs for inducing CD34-positive adult stem cell expansion
JP7364198B2 (ja) ｉＰＳ細胞の生成に使用される新規ＲＮＡ組成物およびその製造方法
US20160289682A1 (en) Production and utilization of a novel anti-cancer drug in therapy

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20180801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125